Letter to the EditorReply to Ege Can Serefoglu, Gregory C. Mitchell, and Wayne J.G. Hellstrom’s Letter to the Editor re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011;60:1105–13
Section snippets
Conflicts of interest
Hartmut Porst is an investigator, speaker, and consultant for Eli Lilly and Company, Bayer Health-Care, and Pfizer. Edward D. Kim is an investigator, speaker, and consultant for Eli Lilly and Company and a speaker for Watson and Astellas Pharma Inc. Adolfo R. Casabé is an investigator, speaker, and consultant for Eli Lilly and Company, GlaxoSmithKline, Janssen, and Pfizer. Vincenzo Mirone is a consultant, investigator, and speaker for Eli Lilly and Company and Bayer Health-Care. Roberta J.
References (7)
- et al.
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial
Eur Urol
(2011) - et al.
Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients?
J Urol
(1995) - et al.
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study
J Urol
(2008)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.